A very effective EGFR TKI (TKI) known as Tagrisso, also referred to as Tagrisso, has revolutionized the treatment of cancer of the lungs in patients with changes in EGFR.trials have shown significant results with this new medication, offering hope to patients previously resistant to other treatments.This article will explore the significance of Tagrisso, its mechanism of action, and its function in the treatment of cancer of the lungs.AstraZeneca created Tagrisso, a second gen EGFR TKI (TKI), which affects the EGFR mutation that is commonly changed in non-small cell cancer of…
